Balanced news tone
News Sentiment
AORT sentiment intelligence
Artivion Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
60
Balanced news tone
60 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+0.5% over one week, +19.9% over four weeks, trend inactive, and near fair-value range.
Artivion (AORT) Corporate presentation Summary
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Earnings
76/100 classification
One-week reaction
0.5%
Price digesting
Trend fit
Trend inactive
19.9% over four weeks
Fair value
-13.1%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
21
Neutral
35
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quartr
Direct company coverage
Artivion (AORT) Corporate presentation Summary
Artivion (AORT) presented a summary of its financial performance, growth strategies, and product innovation, highlighting its specialization in aortic disease. The company reported FY25 revenue of $444 million and projected FY26 revenue of $480–496 million, with strong EBITDA gro
- Tone
- Positive 81/100
- Event
- Earnings
- Published
- 16 Jul 2026 03:40
- Source
- Quartr
Market source
Industry context
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
Moomoo
Direct company coverage
Artivion (AORT) Stock Forum and Discussion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 12:46
- Source
- Moomoo
Simply Wall Street
Direct company coverage
Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device
Artivion (AORT) received full U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, opening up a potential $150 million annual market and strengthening its growth prospects. Despite this positive clinical development, the company's recent removal from Russell indices could
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 11:11
- Source
- Simply Wall Street
Kalkine Media
Direct company coverage
What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval?
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 05:12
- Source
- Kalkine Media
Simply Wall Street
Direct company coverage
Artivion (AORT) Wins FDA Approval, Is The Stock Still 53% Undervalued?
Artivion (AORT) recently received FDA premarket approval for its AMDS Hybrid Prosthesis, a move that has drawn significant attention to the stock. Despite a 19.14% increase in the last 30 days, the share price is still down 46.09% year-to-date and trades significantly below its U
- Tone
- Positive 77/100
- Event
- Regulatory and legal
- Published
- 05 Jul 2026 22:40
- Source
- Simply Wall Street
Stock Titan
Direct company coverage
Artivion’s AMDS gets FDA approval for deadly aortic tears
Artivion (NYSE: AORT) recently received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion, a condition affecting approximately 60% of such cases. This approval eliminates the need for Institutional Re
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 11:12
- Source
- Stock Titan
MSN
Direct company coverage
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth
Artivion has increased its 2025 revenue guidance to $435 million–$443 million, driven by strong double-digit growth in its On-X heart valve and stent graft product lines. The company also reported Q4 2023 revenue of $85.6 million and full-year 2023 revenue of $334.2 million, surp
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 20:10
- Source
- MSN
Market source
Direct company coverage
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospi
- Tone
- Positive 77/100
- Event
- Regulatory and legal
- Published
- 01 Jul 2026 14:40
- Source
- Market source
Vascular News
Direct company coverage
Artivion announces US FDA approval of AMDS hybrid prosthesis
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 10:01
- Source
- Vascular News
Moomoo
Direct company coverage
Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell
Artivion (AORT) announced that its AMDS hybrid prosthesis device has received U.S. Food and Drug Administration (FDA) premarket approval. The device is designed to treat thoracoabdominal aortic aneurysm (TAAA) disease. Following the announcement, shares of Artivion were up over 7
- Tone
- Positive 82/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 08:40
- Source
- Moomoo
Seeking Alpha
Direct company coverage
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT)
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 30 Jun 2026 07:00
- Source
- Seeking Alpha
TradingView
Direct company coverage
Enterprise value to revenue forward of Artivion, Inc. – SWB:CYL
This article provides financial information for Artivion, Inc. (SWB:CYL) on the Stuttgart Stock Exchange. It specifically highlights the enterprise value to revenue forward metric for the company. The content appears to be a financial data point or a brief note from a financial p
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 00:09
- Source
- TradingView
Sahm
Direct company coverage
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion Inc. received FDA approval for its AMDS Hybrid Prosthesis, which treats acute DeBakey Type I aortic dissections, removing previous institutional review board requirements and easing access for hospitals. This approval validates clinical benefits observed in the PERSEVERE
- Tone
- Positive 73/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 21:41
- Source
- Sahm
Finviz
Direct company coverage
AORT - Artivion Inc Options
This article provides an overview of Artivion Inc. (AORT) stock options, displaying key financial metrics and performance indicators as of June 30, 2026. It includes data on market capitalization, earnings, sales, insider and institutional ownership, and various price performance
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 20:10
- Source
- Finviz
Simply Wall Street
Direct company coverage
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis
Artivion (AORT) shares rose 17.3% after receiving full FDA premarket approval for its AMDS Hybrid Prosthesis for acute DeBakey Type I aortic dissections, eliminating the need for prior hospital IRB approval. This approval validates the device's trial data, which showed significan
- Tone
- Positive 82/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 17:40
- Source
- Simply Wall Street
Medical Product Outsourcing
Direct company coverage
Artivion Wins FDA Nod for AMDS Hybrid Prosthesis
Artivion has received U.S. FDA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This device is the first aortic arch remodeling device for this condition and has shown significant reductions in mortality and major adverse events
- Tone
- Positive 95/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 14:40
- Source
- Medical Product Outsourcing
TradingPedia
Direct company coverage
Artivion Shares Rise After FDA Approves AMDS Aortic Device
Artivion Inc. (NYSE: AORT) saw its shares rise after the FDA approved its AMDS Hybrid Prosthesis for treating acute DeBakey Type I aortic dissections, particularly those involving malperfusion. This approval removes the need for institutional review board authorization, broadenin
- Tone
- Positive 87/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 14:40
- Source
- TradingPedia
www.marketscreener.com
Direct company coverage
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index
Artivion, Inc. (NYSE: AORT), a medical device company specializing in aortic diseases, has been removed from the Russell Microcap Value Benchmark Index. This news follows several other recent index removals for Artivion from benchmarks such as the Russell 2000 Defensive Index, Ru
- Tone
- Negative 26/100
- Event
- Market update
- Published
- 29 Jun 2026 12:40
- Source
- www.marketscreener.com
grafa.com
Direct company coverage
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections
Artivion (NYSE:AORT) has received U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion. This approval eliminates HDE-related institutional review board requirements and is supported by data from th
- Tone
- Positive 92/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 11:59
- Source
- grafa.com
PR Newswire
Direct company coverage
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion, Inc. announced that the U.S. FDA has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device for treating acute DeBakey Type I aortic dissections. This approval removes the previous requirement for hospitals to obtain IRB approval, fac
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 10:40
- Source
- PR Newswire
Investing.com
Direct company coverage
Artivion receives FDA approval for aortic dissection device
Artivion, Inc. (NYSE: AORT) has received FDA approval for its AMDS Hybrid Prosthesis, a device designed to treat acute DeBakey Type I aortic dissections, particularly those with clinical or radiographic malperfusion. This approval, based on positive data from the PERSEVERE U.S. I
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 07:20
- Source
- Investing.com
TradingView
Direct company coverage
Price to earnings forward of Artivion, Inc. – NYSE:AORT
This page provides financial data for Artivion, Inc. (NYSE: AORT), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, offering an overview of the company's financials for investors and traders.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 20:40
- Source
- TradingView
TradingView
Direct company coverage
Artivion, Inc. Actuals & Estimates (NYSE:AORT)
This article provides an overview of Artivion, Inc. (AORT) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, upcoming earnings reports, and financial metrics such as revenue, net income, and EBITDA, while cla
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:10
- Source
- TradingView
TradingView
Direct company coverage
AORT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Artivion, Inc. (AORT) stock, including analyst price targets, historical performance, and key financial metrics. According to 8 analysts, AORT has a max price estimate of $48.00 and a min estimate of $36.00. The article also details the compan
- Tone
- Positive 61/100
- Event
- Analyst action
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
TradingKey
Direct company coverage
Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Artivion Inc (AORT), showing its performance by business segment and geographical region. As of the latest update (Mon, Apr 6), the company's major revenue contributors are Aortic stent grafts, On X, and Preservation Services
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 09:40
- Source
- TradingKey
Investing.com
Direct company coverage
Artivion’s Andrew Green sells $910,738 in company stock
Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold company common stock totaling $910,738 on June 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved 44,001 shares at weighted average prices between $20.694 and $20.707. Pr
- Tone
- Negative 39/100
- Event
- Regulatory and legal
- Published
- 16 Jun 2026 14:40
- Source
- Investing.com
Investing.com India
Direct company coverage
Artivion’s Andrew Green sells $910,738 in company stock By Investing.com
Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold 44,001 shares of company stock for $910,738 on June 11, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he acquired the same number of shares through stock option exercises for $589,07
- Tone
- Negative 39/100
- Event
- Regulatory and legal
- Published
- 15 Jun 2026 16:40
- Source
- Investing.com India
MT Newswires
Direct company coverage
Artivion Insider Sold Shares Worth $910,739, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 15:36
- Source
- MT Newswires
Stock Titan
Direct company coverage
Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan
Artivion, Inc. (AORT) Senior Vice President Andrew M. Green executed a pre-arranged transaction under a Rule 10b5-1 trading plan, exercising stock options for 44,001 shares and subsequently selling all of these shares in open-market transactions. The sales occurred on June 11, 20
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 15:40
- Source
- Stock Titan